[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2024003887A - Células inmunitarias que tienen arnch coespresados y sistemas de compuerta lógica. - Google Patents

Células inmunitarias que tienen arnch coespresados y sistemas de compuerta lógica.

Info

Publication number
MX2024003887A
MX2024003887A MX2024003887A MX2024003887A MX2024003887A MX 2024003887 A MX2024003887 A MX 2024003887A MX 2024003887 A MX2024003887 A MX 2024003887A MX 2024003887 A MX2024003887 A MX 2024003887A MX 2024003887 A MX2024003887 A MX 2024003887A
Authority
MX
Mexico
Prior art keywords
immune cells
logic gate
bind
gate systems
shrna
Prior art date
Application number
MX2024003887A
Other languages
English (en)
Inventor
Natalie Bezman
Aaron Cooper
Katherine Harris
John Gagnon
Michelle Nguyen
Anzhi Yao
Stephen Santoro
Nicole Allen
Chaudhry Harbani Kaur Malik
Jasper Williams
Adam Litterman
Omar Khan
Original Assignee
Arsenal Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arsenal Biosciences Inc filed Critical Arsenal Biosciences Inc
Publication of MX2024003887A publication Critical patent/MX2024003887A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464463—Phosphatases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/464468—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En la presente se proporcionan ácidos nucleicos recombinantes que codifican receptores cebadores quiméricos que se unen a ALPG/P, receptores de antígenos quiméricos que se unen a MSLN y ARNhc que se dirigen a FAS, PTPN2 y/o TOX. También se proporcionan sistemas de receptores cebadores quiméricos que se unen a ALPG/P, receptores de antígenos quiméricos que se unen a MSLN y ARNhc que se dirigen a FAS, PTPN2 y/o TOX, células que expresan dichas proteínas y ARNhc, y métodos de uso de estos.
MX2024003887A 2021-10-14 2022-10-14 Células inmunitarias que tienen arnch coespresados y sistemas de compuerta lógica. MX2024003887A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163255887P 2021-10-14 2021-10-14
US202163255889P 2021-10-14 2021-10-14
US202163255891P 2021-10-14 2021-10-14
US202263303422P 2022-01-26 2022-01-26
PCT/US2022/078158 WO2023064928A2 (en) 2021-10-14 2022-10-14 Immune cells having co-expressed shrnas and logic gate systems

Publications (1)

Publication Number Publication Date
MX2024003887A true MX2024003887A (es) 2024-07-09

Family

ID=85988930

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024003887A MX2024003887A (es) 2021-10-14 2022-10-14 Células inmunitarias que tienen arnch coespresados y sistemas de compuerta lógica.

Country Status (14)

Country Link
US (2) US12037407B2 (es)
EP (1) EP4416292A2 (es)
JP (1) JP2024537991A (es)
KR (1) KR20240099259A (es)
AU (1) AU2022366987A1 (es)
CA (1) CA3232968A1 (es)
CL (1) CL2024000841A1 (es)
CO (1) CO2024006024A2 (es)
CR (1) CR20240195A (es)
DO (1) DOP2024000057A (es)
IL (1) IL311570A (es)
MX (1) MX2024003887A (es)
PE (1) PE20241173A1 (es)
WO (1) WO2023064928A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023205724A2 (en) * 2022-04-20 2023-10-26 Arsenal Biosciences, Inc. Cells comprising a suppressor of gene expression and/or a synthetic pathway activator and/or an inducible payload

Family Cites Families (229)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5081227A (en) 1988-03-04 1992-01-14 La Jolla Cancer Research Foundation Germ cell alkaline phosphatase
ATE123815T1 (de) 1989-11-17 1995-06-15 Unilever Nv Spezifische bindende wirkstoffe.
US6773669B1 (en) 1995-03-10 2004-08-10 Maxcyte, Inc. Flow electroporation chamber and method
US6090617A (en) 1996-12-05 2000-07-18 Entremed, Inc. Flow electroporation chamber with electrodes having a crystalline metal nitride coating
US20020004490A1 (en) 1999-04-12 2002-01-10 Dean Nicholas M. Antisense modulation of Fas mediated signaling
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
WO2000044914A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
WO2000073346A1 (en) 1999-05-27 2000-12-07 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Immunoconjugates having high binding affinity
WO2001029058A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US8202846B2 (en) 2000-03-16 2012-06-19 Cold Spring Harbor Laboratory Methods and compositions for RNA interference
US20020064802A1 (en) 2000-04-28 2002-05-30 Eva Raschke Methods for binding an exogenous molecule to cellular chromatin
US7029916B2 (en) 2001-02-21 2006-04-18 Maxcyte, Inc. Apparatus and method for flow electroporation of biological samples
WO2002086134A2 (de) 2001-04-23 2002-10-31 Amaxa Gmbh Pufferlössung für die elektroporation und verfahren umfassend die verwendung derselben
KR100385905B1 (ko) 2001-05-17 2003-06-02 주식회사 웰진 유니진 유래의 안티센스 분자로 구성된 안티센스 라이브러리를 이용한 대규모 유전자 검색 및 기능 분석 방법
US6485974B1 (en) 2001-05-18 2002-11-26 Isis Pharmaceuticals, Inc. Antisense modulation of PTPN2 expression
DK1456345T3 (en) 2001-08-22 2016-09-26 Maxcyte Inc Apparatus and method for electroporation of biological samples
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
GB0124391D0 (en) 2001-10-11 2001-11-28 Gene Expression Technologies L Control of gene expression
US20050136040A1 (en) 2001-10-11 2005-06-23 Imperial College Innovations Limited Control of gene expression using a complex of an oligonucleotide and a regulatory peptide
WO2003046173A1 (fr) 2001-11-28 2003-06-05 Center For Advanced Science And Technology Incubation, Ltd. Systeme d'expression d'arn si et procede de production de cellules d'inactivation de genes fonctionnelles et analogues au moyen de ce systeme
AU2003218382B2 (en) 2002-03-21 2007-12-13 Sangamo Therapeutics, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
WO2004016735A2 (en) 2002-05-23 2004-02-26 Ceptyr, Inc. Modulation of biological signal transduction by rna interference
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
AU2003282722A1 (en) 2002-10-02 2004-04-23 Alnylam Pharmaceuticals Inc. Therapeutic compositions
ITMI20030821A1 (it) 2003-04-18 2004-10-19 Internat Ct For Genetic En Gineering And Polipeptidi chimerici e loro uso.
EP1631676A4 (en) 2003-06-10 2006-12-20 Toolgen Inc TRANSDUCIBLE DNA BINDING PROTEINS
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
DE502004009820D1 (de) 2004-03-15 2009-09-10 Lonza Cologne Ag Behältnis und Vorrichtung zur Erzeugung von elektrischen Feldern in einzelnen Reaktionsräumen
EP1766057B1 (en) 2004-05-12 2014-12-17 Maxcyte, Inc. Methods and devices related to a regulated flow electroporation chamber
AU2005257583A1 (en) 2004-06-12 2006-01-05 Digital Bio Technology Co., Ltd. Electroporator having an elongated hollow member
WO2005123962A2 (en) 2004-06-14 2005-12-29 The University Of Texas At Austin Gene targeting in eukaryotic cells by group ii intron ribonucleoprotein particles
EP1607484B1 (de) 2004-06-14 2014-04-02 Lonza Cologne GmbH Verfahren und Schaltungsanordnung zur Behandlung von biologischem Material
JP2008521437A (ja) 2004-11-30 2008-06-26 マックスサイト インコーポレーティッド コンピュータ化されたエレクトロポレーション
AU2005316384B2 (en) 2004-12-14 2012-02-09 Alnylam Pharmaceuticals, Inc. RNAi modulation of MLL-AF4 and uses thereof
EP1885758A2 (en) 2005-05-12 2008-02-13 The Government of the United States of America as Represented by The Department of Health and Human Services Anti-mesothelin antibodies useful for immunological assays
EP2397155B1 (en) 2005-06-08 2017-12-13 Dana-Farber Cancer Institute, Inc. Methods and compositions for the treatment of persistent infections by inhibiting the programmed cell death 1 (PD-1)pathway
US10022457B2 (en) 2005-08-05 2018-07-17 Gholam A. Peyman Methods to regulate polarization and enhance function of cells
DK2325332T3 (da) 2005-08-26 2013-01-28 Dupont Nutrition Biosci Aps Anvendelse af CRISPR-associerede gener (CAS)
US20070161031A1 (en) 2005-12-16 2007-07-12 The Board Of Trustees Of The Leland Stanford Junior University Functional arrays for high throughput characterization of gene expression regulatory elements
CA2660485C (en) 2006-08-11 2016-04-12 Sangamo Biosciences, Inc. Zinc finger nuclease-mediated homologous recombination
US8252526B2 (en) 2006-11-09 2012-08-28 Gradalis, Inc. ShRNA molecules and methods of use thereof
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
US20100105134A1 (en) 2007-03-02 2010-04-29 Mdrna, Inc. Nucleic acid compounds for inhibiting gene expression and uses thereof
WO2008109532A2 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting fas gene expression and uses thereof
DK2279253T3 (en) 2008-04-09 2017-02-13 Maxcyte Inc Construction and application of therapeutic compositions of freshly isolated cells
DK2310500T3 (en) 2008-07-18 2015-05-11 Maxcyte Inc Process for optimizing electroporation
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
EP2424877A4 (en) 2009-04-28 2013-01-02 Harvard College SUPERCHARGED PROTEINS FOR CELL PENETRATION
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
US8586363B2 (en) 2009-12-10 2013-11-19 Regents Of The University Of Minnesota TAL effector-mediated DNA modification
US9290748B2 (en) 2010-02-26 2016-03-22 Cellectis Use of endonucleases for inserting transgenes into safe harbor loci
CN102939377B (zh) 2010-04-26 2016-06-08 桑格摩生物科学股份有限公司 使用锌指核酸酶对Rosa位点进行基因组编辑
LT2649086T (lt) 2010-12-09 2017-11-10 The Trustees Of The University Of Pennsylvania Chimeriniu antigenų receptoriumi modifikuotų ląstelių naudojimas vėžio gydymui
RU2688185C2 (ru) 2011-03-23 2019-05-21 Фред Хатчинсон Кэнсер Рисерч Сентер Способ и композиции для клеточной иммунотерапии
WO2013063419A2 (en) 2011-10-28 2013-05-02 The Trustees Of The University Of Pennsylvania A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
EP2817331B1 (en) 2012-02-22 2023-08-30 The Trustees of the University of Pennsylvania Use of the cd2 signaling domain in second-generation chimeric antigen receptors
SG11201404285VA (en) 2012-02-22 2014-10-30 Univ Pennsylvania Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
MX2014010181A (es) 2012-02-22 2015-03-20 Univ Pennsylvania Uso de cars a base de icos para incrementar la actividad antitumor y persistencia a car.
US20130236504A1 (en) 2012-03-06 2013-09-12 Medical University Of South Carolina Delivery System for Enhancing Drug Efficacy
EP2828290B1 (en) 2012-03-23 2018-08-15 The United States of America, represented by the Secretary, Department of Health and Human Services Anti-mesothelin chimeric antigen receptors
PL3401400T3 (pl) 2012-05-25 2019-12-31 The Regents Of The University Of California Sposób i kompozycje do modyfikacji docelowego dna przez ukierunkowujący RNA oraz do modulacji transkrypcji przez ukierunkowujący RNA
KR102332322B1 (ko) 2012-07-13 2021-12-01 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 형질도입된 ｔ 세포의 투여 적합성을 평가하는 방법
EA201590208A1 (ru) 2012-07-13 2015-11-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Усиление активности т-клеток car путем совместного введения биспецифического антитела
IL237315B (en) 2012-08-20 2022-07-01 Hutchinson Fred Cancer Res Method and preparations for cellular immunotherapy
CN105026429B (zh) 2012-08-21 2018-09-25 美国政府(由卫生和人类服务部的部长所代表) 间皮素结构域-特异性单克隆抗体及其用途
EP2900695B1 (en) 2012-09-27 2018-01-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin antibodies and methods for eliciting potent antitumor activity
WO2014055657A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
PL2912175T3 (pl) 2012-10-23 2019-03-29 Toolgen Incorporated Kompozycja do rozszczepiania DNA docelowego zawierająca naprowadzający RNA specyficzny względem DNA docelowego i kwas nukleinowy kodujący białko Cas lub białko Cas, oraz jej zastosowanie
US20160002626A1 (en) 2012-11-28 2016-01-07 Youwen Zhou Tox inhibition for the treatment of cancer
US9255250B2 (en) 2012-12-05 2016-02-09 Sangamo Bioscience, Inc. Isolated mouse or human cell having an exogenous transgene in an endogenous albumin gene
PL3360964T3 (pl) 2012-12-06 2020-03-31 Sigma-Aldrich Co. Llc Modyfikacja i regulacja genomu oparta na crispr
EP3825401A1 (en) 2012-12-12 2021-05-26 The Broad Institute, Inc. Crispr-cas component systems, methods and compositions for sequence manipulation
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
DK2931891T3 (da) 2012-12-17 2019-08-19 Harvard College Rna-styret modificering af menneskelige genomer
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
AU2014214850C1 (en) 2013-02-06 2018-12-06 Celgene Corporation Modified T lymphocytes having improved specificity
WO2014124267A1 (en) 2013-02-07 2014-08-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Method for diagnosis, prognosis and determination of treatment for cutaneous t-cell lymphoma
LT3300745T (lt) 2013-02-15 2019-12-10 Univ California Chimerinis antigeno receptorius ir jo panaudojimo būdai
US9844569B2 (en) 2013-03-01 2017-12-19 The United State Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing enriched populations of tumor reactive T cells from peripheral blood
JP2016513458A (ja) 2013-03-10 2016-05-16 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 化学療法耐性免疫細胞
US20160145348A1 (en) 2013-03-14 2016-05-26 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
US9745368B2 (en) 2013-03-15 2017-08-29 The Trustees Of The University Of Pennsylvania Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
EP2970208A4 (en) 2013-03-15 2016-11-30 Gen Hospital Corp SPECIFICITY INCREASES FOR RNA-MEDIATED CHANGES
US9937207B2 (en) 2013-03-21 2018-04-10 Sangamo Therapeutics, Inc. Targeted disruption of T cell receptor genes using talens
CA2908403A1 (en) 2013-04-02 2014-10-09 Bayer Cropscience Nv Targeted genome engineering in eukaryotes
DK2981607T3 (da) 2013-04-03 2020-11-16 Memorial Sloan Kettering Cancer Center Effektiv generering af tumormålrettede t-celler afledt af pluripotente stamceller
DK2997134T3 (da) 2013-05-14 2020-09-28 Univ Texas Human anvendelse af genmanipulerede kimære antigenreceptor-(car)-t-celler
ES2883131T3 (es) 2013-05-29 2021-12-07 Cellectis Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN
CA2913830C (en) 2013-05-29 2021-06-29 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
CN105431524B (zh) 2013-06-10 2020-04-21 达娜-法勃肿瘤研究所公司 用于降低肿瘤细胞的免疫抑制的方法和组合物
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
WO2015048690A1 (en) 2013-09-27 2015-04-02 The Regents Of The University Of California Optimized small guide rnas and methods of use
US9957526B2 (en) 2013-10-17 2018-05-01 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
CA2930590C (en) 2013-11-15 2021-02-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Engineering neural stem cells using homologous recombination
US10787684B2 (en) 2013-11-19 2020-09-29 President And Fellows Of Harvard College Large gene excision and insertion
JP2017501149A (ja) 2013-12-12 2017-01-12 ザ・ブロード・インスティテュート・インコーポレイテッド 粒子送達構成成分を用いた障害及び疾患の標的化のためのｃｒｉｓｐｒ−ｃａｓ系及び組成物の送達、使用及び治療適用
KR20160097338A (ko) 2013-12-12 2016-08-17 더 브로드 인스티튜트, 인코퍼레이티드 뉴클레오티드 반복 장애에서의 ｃｒｉｓｐｒ-ｃａｓ 시스템의 조성물 및 방법 및 용도
CA2932478A1 (en) 2013-12-12 2015-06-18 Massachusetts Institute Of Technology Delivery, use and therapeutic applications of the crispr-cas systems and compositions for genome editing
EP3080271B1 (en) 2013-12-12 2020-02-12 The Broad Institute, Inc. Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
EP3080256B1 (en) 2013-12-13 2018-06-13 Cellectis Cas9 nuclease platform for microalgae genome engineering
CA3225456A1 (en) 2013-12-19 2015-06-25 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
JP6793902B2 (ja) 2013-12-20 2020-12-02 ノバルティス アーゲー 調節可能キメラ抗原受容体
EP3083691A2 (en) 2013-12-20 2016-10-26 Cellectis Method of engineering multi-input signal sensitive t cell for immunotherapy
DK3690056T5 (da) 2014-01-31 2024-08-26 Factor Bioscience Inc Fremgangsmåder og produkter til fremstilling og indgivelse af nukleinsyre
WO2015115903A1 (en) 2014-02-03 2015-08-06 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Site-specific dna break-induced genome editing using engineered nucleases
AU2015220762B2 (en) 2014-02-21 2019-05-02 Cellectis Method for in situ inhibition of regulatory T cells
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
SI3129470T1 (sl) 2014-04-07 2021-08-31 Novartis Ag Zdravljenje raka z uporabo antigenskega himernega receptorja proti-cd19
NZ725079A (en) 2014-04-10 2018-03-23 Seattle Children’S Hospital Dba Seattle Children’S Res Institute Transgene genetic tags and methods of use
SG10201809157VA (en) 2014-04-18 2018-11-29 Editas Medicine Inc Crispr-cas-related methods, compositions and components for cancer immunotherapy
JP2017524348A (ja) 2014-06-10 2017-08-31 モナッシュ ユニバーシティ 養子細胞移入のためのｐｔｐｎ２阻害を用いた白血球の産生方法
US10570418B2 (en) 2014-09-02 2020-02-25 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification
WO2016049251A1 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
WO2016057951A2 (en) 2014-10-09 2016-04-14 Life Technologies Corporation Crispr oligonucleotides and gene editing
KR20240075936A (ko) 2014-10-31 2024-05-29 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Cart 세포에서 유전자 발현의 변경 및 그의 용도
WO2016097751A1 (en) 2014-12-18 2016-06-23 The University Of Bath Method of cas9 mediated genome engineering
CN107530436B (zh) 2015-01-21 2022-03-29 菲泽尔克斯公司 用于将治疗剂和诊断剂递送到细胞中的方法、组合物和系统
US10377988B2 (en) 2015-01-23 2019-08-13 Musc Foundation For Research Development Cytokine receptor genes and the use thereof to enhance therapy
EP3250693B2 (en) 2015-01-30 2023-12-20 The Regents of The University of California Protein delivery in primary hematopoietic cells
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
EP3262173A2 (en) 2015-02-23 2018-01-03 Crispr Therapeutics AG Materials and methods for treatment of human genetic diseases including hemoglobinopathies
US10590182B2 (en) 2015-02-24 2020-03-17 The Regents Of The University Of California Binding-triggered transcriptional switches and methods of use thereof
WO2016172359A2 (en) 2015-04-24 2016-10-27 The Regents Of The University Of California Systems for detecting, monitoring or treating diseases or conditions using engineered cells and methods for making and using them
JP7121496B2 (ja) 2015-05-28 2022-08-18 アルモ・バイオサイエンシーズ・インコーポレイテッド 癌治療で使用するためのペグ化インターロイキン－１０
KR20220008388A (ko) 2015-05-28 2022-01-20 카이트 파마 인코포레이티드 T 세포 요법을 위해 환자를 컨디셔닝하는 방법
WO2016196388A1 (en) 2015-05-29 2016-12-08 Juno Therapeutics, Inc. Composition and methods for regulating inhibitory interactions in genetically engineered cells
WO2016205703A1 (en) 2015-06-17 2016-12-22 The Uab Research Foundation Crispr/cas9 complex for genomic editing
AU2016278959A1 (en) 2015-06-17 2018-01-18 The Uab Research Foundation CRISPR/Cas9 complex for introducing a functional polypeptide into cells of blood cell lineage
CA2986314C (en) 2015-06-30 2024-04-23 Cellectis Methods for improving functionality in nk cell by gene inactivation using specific endonuclease
US20170000743A1 (en) 2015-07-02 2017-01-05 Vindico NanoBio Technology Inc. Compositions and Methods for Delivery of Gene Editing Tools Using Polymeric Vesicles
CA2991301A1 (en) 2015-07-13 2017-01-19 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
CN107207613B (zh) 2015-08-07 2020-06-09 深圳市体内生物医药科技有限公司 含Toll样受体胞内结构域的嵌合抗原受体
JO3799B1 (ar) 2015-08-17 2021-01-31 Janssen Pharmaceutica Nv الأجسام المضادة ل bcma، جزيئات ربط الانتيجين ثنائية التحديد التي تربط bcma و cd3، و استخداماتها
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
WO2017035659A1 (en) 2015-09-01 2017-03-09 The Hospital For Sick Children Method and compositions for removing duplicated copy number variations (cnvs) for genetic disorders and related uses
MX2018003353A (es) * 2015-09-17 2018-09-17 Novartis Ag Terapias con celulas cart con una eficacia mejorada.
WO2017053729A1 (en) 2015-09-25 2017-03-30 The Board Of Trustees Of The Leland Stanford Junior University Nuclease-mediated genome editing of primary cells and enrichment thereof
WO2017058751A1 (en) 2015-09-28 2017-04-06 North Carolina State University Methods and compositions for sequence specific antimicrobials
EP3359184B1 (en) 2015-10-05 2020-05-06 Precision Biosciences, Inc. Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene
WO2017070169A1 (en) 2015-10-19 2017-04-27 The Methodist Hospital Crispr-cas9 delivery to hard-to-transfect cells via membrane deformation
US20180312873A1 (en) 2015-10-20 2018-11-01 10X Genomics, Inc. Method and systems for high throughput single cell genetic manipulation
WO2017070429A1 (en) 2015-10-22 2017-04-27 Regents Of The University Of Minnesota Methods involving editing polynucleotides that encode t cell receptor
EP4249074A3 (en) 2015-11-04 2024-01-10 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
SG11201804372PA (en) 2015-11-23 2018-06-28 Univ California Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9
ES2975747T3 (es) 2015-11-30 2024-07-12 Univ California Administración de carga útil específica de tumor y activación inmunitaria utilizando un anticuerpo humano que se dirige a un antígeno de superficie celular de tumor altamente específico
US11352631B2 (en) 2015-12-18 2022-06-07 Sangamo Therapeutics, Inc. Targeted disruption of the T cell receptor
CN116676292A (zh) 2015-12-30 2023-09-01 阿维塔斯有限公司 基因编辑蛋白和组合物向细胞和组织的无载体递送
AU2017230011A1 (en) 2016-03-11 2018-09-27 2Seventy Bio, Inc. Genome edited immune effector cells
US20170267755A1 (en) 2016-03-16 2017-09-21 Sri International Isolated anti-mesothelin antibodies, conjugates and uses thereof
AU2017248259A1 (en) 2016-04-07 2018-10-25 Bluebird Bio, Inc. Chimeric antigen receptor T cell compositions
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
CR20180503A (es) 2016-04-14 2018-12-21 Hutchinson Fred Cancer Res Composiciones y métodos para programar células terapéuticas utilizando nanoportadores de ácidos nucleicos dirigidos
SG11201808831TA (en) 2016-04-15 2018-11-29 Memorial Sloan Kettering Cancer Center Transgenic t cell and chimeric antigen receptor t cell compositions and related methods
WO2017189336A1 (en) 2016-04-25 2017-11-02 The Regents Of The University Of California Methods and compositions for genomic editing
CN109715803B (zh) 2016-04-25 2023-07-07 巴塞尔大学 等位基因编辑及其应用
AU2017256517B2 (en) 2016-04-29 2023-09-28 Basf Plant Science Company Gmbh Improved methods for modification of target nucleic acids
EP3452499A2 (en) 2016-05-06 2019-03-13 Juno Therapeutics, Inc. Genetically engineered cells and methods of making the same
EP3463667A1 (en) 2016-05-31 2019-04-10 Massachusetts Institute of Technology Hydrodynamically controlled electric fields for high throughput transformation&high throughput parallel transformation platform
EP3472338B1 (en) 2016-06-20 2024-05-22 Octapharma AG Means and methods for modifying multiple alleles
US20170362635A1 (en) 2016-06-20 2017-12-21 University Of Washington Muscle-specific crispr/cas9 editing of genes
WO2018002719A1 (en) 2016-06-29 2018-01-04 Crispr Therapeutics Ag Compositions and methods for gene editing
WO2018007263A1 (en) 2016-07-06 2018-01-11 Cellectis Sequential gene editing in primary immune cells
CN110312799A (zh) 2016-08-17 2019-10-08 博德研究所 新型crispr酶和系统
US11999931B2 (en) 2016-08-20 2024-06-04 The Regents Of The University Of California High-throughput system and method for the temporary permeabilization of cells
CA3034093A1 (en) 2016-08-23 2018-03-01 The Regents Of The University Of California Proteolytically cleavable chimeric polypeptides and methods of use thereof
WO2018049025A2 (en) 2016-09-07 2018-03-15 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses
US20180127786A1 (en) 2016-09-23 2018-05-10 Casebia Therapeutics Limited Liability Partnership Compositions and methods for gene editing
ES2875959T3 (es) 2016-10-07 2021-11-11 Tcr2 Therapeutics Inc Composiciones y métodos para reprogramación de receptores de linfocitos T mediante el uso de proteínas de fusión
JP7177047B2 (ja) 2016-10-12 2022-11-22 フェルダン・バイオ・インコーポレーテッド ポリペプチドカーゴを標的真核細胞の細胞外間隙からサイトゾルおよび／または核に送達するための合理的に設計された合成ペプチドシャトル剤、その使用、それに関連する方法およびキット
WO2018073391A1 (en) 2016-10-19 2018-04-26 Cellectis Targeted gene insertion for improved immune cells therapy
WO2018073393A2 (en) 2016-10-19 2018-04-26 Cellectis Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
WO2018094291A1 (en) 2016-11-18 2018-05-24 Christopher Bradley Massively multiplexed homologous template repair for whole-genome replacement
RU2019121992A (ru) 2016-12-14 2021-01-15 Лигандал, Инк. Способы и композиции для доставки полезной нагрузки в виде нуклеиновых кислот и белков
EP4183798A1 (en) 2017-01-09 2023-05-24 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-mesothelin immunotherapy
CN118389602A (zh) 2017-05-08 2024-07-26 株式会社图尔金 经人工操纵的免疫细胞
US10858443B2 (en) 2017-05-31 2020-12-08 Trustees Of Boston University Synthetic notch protein for modulating gene expression
BR112019026625A2 (pt) 2017-06-15 2020-06-30 The Regents Of The University Of California inserções de dna não viral direcionadas
WO2019079034A1 (en) 2017-10-17 2019-04-25 The General Hospital Corporation METHODS AND COMPOSITIONS RELATING TO GENETICALLY MODIFIED REGULATORY T LYMPHOCYTES
US20210071139A1 (en) 2017-10-27 2021-03-11 The Trustees Of The University Of Pennsylvania Identifying Epigenetic And Transcriptional Targets To Prevent And Reverse T Cell Exhaustion
MX2020004325A (es) 2017-10-27 2020-11-09 Univ California Reemplazo dirigido de receptores de células t endógenos.
EP3714042A4 (en) 2017-11-22 2021-08-04 La Jolla Institute for Allergy and Immunology USE AND PRODUCTION OF MODIFIED IMMUNE CELLS
JP7068498B2 (ja) 2018-01-12 2022-05-16 クロセル インク． 二重ｓｈＲＮＡを用いて強化された免疫細胞及びそれを含む組成物
US20200399383A1 (en) * 2018-02-13 2020-12-24 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
WO2019164979A1 (en) * 2018-02-21 2019-08-29 Cell Design Labs, Inc. Chimeric transmembrane receptors and uses thereof
SG11202007577QA (en) 2018-03-02 2020-09-29 Generation Bio Co Closed-ended dna (cedna) vectors for insertion of transgenes at genomic safe harbors (gsh) in humans and murine genomes
AU2019236205A1 (en) 2018-03-15 2020-10-08 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
US20210207174A1 (en) 2018-05-25 2021-07-08 The Regents Of The University Of California Genetic engineering of endogenous proteins
CN118184790A (zh) 2018-06-12 2024-06-14 湖南远泰生物技术有限公司 Plap-car-效应细胞
WO2020014235A1 (en) 2018-07-09 2020-01-16 The Regents Of The University Of California Gene targets for t-cell-based immunotherapy
US20220081691A1 (en) 2018-08-07 2022-03-17 Dana-Farber Cancer Institute, Inc Modulating ptpn2 to increase immune responses and perturbing gene expression in hematopoietic stem cell lineages
EP3844282A4 (en) 2018-08-29 2022-06-01 Nanjing Legend Biotech Co., Ltd. ANTI-MESOTHELIN CHIMERAL ANTIGEN RECEPTOR (CAR) CONSTRUCTS AND THEIR USES
CN110904045A (zh) 2018-09-17 2020-03-24 中国科学院动物研究所 经修饰的t细胞、其制备方法及用途
WO2020072125A1 (en) 2018-10-03 2020-04-09 Massachusetts Institute Of Technology Splicing-dependent transcriptional gene silencing or activation
BR112021010297A2 (pt) 2018-11-28 2021-08-24 Board Of Regents, The University Of Texas System Edição de genomas multiplexadores de células imunes para aumentar a funcionalidade e resistência ao ambiente supressivo
WO2020123871A1 (en) 2018-12-12 2020-06-18 The Regents Of The University Of California Compositions and methods for modifying a target nucleic acid
EP3898977A1 (en) 2018-12-20 2021-10-27 Praxis Precision Medicines, Inc. Compositions and methods for the treatment of kcnt1 related disorders
AU2020208616A1 (en) 2019-01-16 2021-08-12 Beam Therapeutics Inc. Modified immune cells having enhanced anti-neoplasia activity and immunosuppression resistance
CN113396216A (zh) 2019-02-04 2021-09-14 Ksq治疗公司 用于改进的免疫疗法的组合基因靶标
US20230066806A1 (en) 2019-03-14 2023-03-02 The Regents Of The University Of California Pooled knock-in screening and heterologous polypeptides co-expressed under the control of endogenous loci
US20220226380A1 (en) 2019-04-24 2022-07-21 St. Jude Children's Research Hospital, Inc. Gene knock-outs to improve t cell function
CA3142986A1 (en) 2019-05-02 2020-11-05 Celyad Cells with multiplexed inhibitory rna
SG11202110935RA (en) * 2019-05-13 2021-10-28 Dna Twopointo Inc Modifications of mammalian cells using artificial micro-rna to alter their properties and the compositions of their products
CA3150095A1 (en) * 2019-09-06 2021-03-11 Shirley O'dea IMMUNE CELL ENGINEERING FOR EX VIVO CELLULAR THERAPY APPLICATIONS
DE102019214466A1 (de) 2019-09-23 2021-03-25 Henkel Ag & Co. Kgaa Mittel zum Färben von keratinischem Material mit Aminosilikon, farbgebender Verbindung und ethoxyliertem Fettsäureester
WO2021061872A1 (en) 2019-09-24 2021-04-01 The Regents Of The University Of California Novel receptors having a heterologous stop transfer sequence for ligand-dependent transcriptional regulation
WO2021061859A1 (en) 2019-09-24 2021-04-01 The Regents Of The University Of California Novel receptors for ligand-dependent transcriptional regulation
WO2021061862A1 (en) 2019-09-24 2021-04-01 The Regents Of The University Of California Notch receptors with hinge domain
WO2021062227A2 (en) 2019-09-27 2021-04-01 Beam Therapeutics Inc. Compositions and methods for treatment of liquid cancers
JP2023502986A (ja) 2019-11-20 2023-01-26 カルセリックス ピーティーワイ． リミテッド 増強された機能を有する免疫細胞を提供する方法
EP4065138A4 (en) 2019-11-27 2024-02-28 Board of Regents, The University of Texas System LARGE-SCALE COMBINED CAR TRANSDUCTION AND CRISPR GENE EDITING OF MSC CELLS
JP2023504782A (ja) 2019-11-27 2023-02-07 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｂ細胞のｃａｒ形質導入とｃｒｉｓｐｒ遺伝子編集との大規模での組み合わせ
CA3163258A1 (en) 2019-11-27 2021-06-03 Board Of Regents, The University Of Texas System Large-scale combined car transduction and crispr gene editing of nk cells
CN115052897B (zh) 2020-01-28 2024-06-21 湖南远泰生物技术有限公司 PLAP-CD3ε双特异性抗体
IL294879A (en) 2020-01-29 2022-09-01 Inhibrx Inc Monodomain antibodies of cd28 and their multivalent and multispecific constructs
AU2021251212A1 (en) 2020-04-09 2022-11-03 The Regents Of The University Of California Humanized Notch receptors with hinge domain
BR112023007874A2 (pt) 2020-10-26 2023-10-24 Arsenal Biosciences Inc Loci de porto seguro
US11332744B1 (en) 2020-10-26 2022-05-17 Arsenal Biosciences, Inc. Safe harbor loci
US20240024476A1 (en) 2021-01-07 2024-01-25 Innovative Cellular Therapeutics Holdings, Ltd. CAR Cells and Polyspecific Binding Molecules for Treating Solid Tumor
US20220235380A1 (en) * 2021-01-26 2022-07-28 Arsenal Biosciences, Inc. Immune cells having co-expressed shrnas and logic gate systems
US20230104938A1 (en) 2021-10-05 2023-04-06 Aristocrat Technologies, Inc. (ATI) Electronic Gaming Machine with Symbols Streaming Adjacent an Active Reel Matrix with Reel Expansion and Symbol Absorption Processes
PE20241177A1 (es) 2021-10-14 2024-05-28 Teneobio Inc Proteinas de union a la mesotelina y usos de las mismas
AR127887A1 (es) 2021-12-10 2024-03-06 Hoffmann La Roche Anticuerpos que se unen a cd3 y plap

Also Published As

Publication number Publication date
CL2024000841A1 (es) 2024-07-19
CO2024006024A2 (es) 2024-05-20
CA3232968A1 (en) 2023-04-20
US20230340139A1 (en) 2023-10-26
EP4416292A2 (en) 2024-08-21
US20240309106A1 (en) 2024-09-19
WO2023064928A3 (en) 2023-09-21
CR20240195A (es) 2024-06-20
KR20240099259A (ko) 2024-06-28
WO2023064928A2 (en) 2023-04-20
IL311570A (en) 2024-05-01
DOP2024000057A (es) 2024-06-30
US12037407B2 (en) 2024-07-16
PE20241173A1 (es) 2024-05-28
AU2022366987A1 (en) 2024-05-16
JP2024537991A (ja) 2024-10-18

Similar Documents

Publication Publication Date Title
GT201700162A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
CL2017001328A1 (es) Anticuerpos heterodimericos que unen cd3 y antígenos tumorales
MX2024010983A (es) Anticuerpos monoclonales de adn dirigidos a moleculas de punto de control.
CL2019000119A1 (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123.
MX2023001360A (es) Anticuerpos anti-c5 y metodos de uso.
SA518391704B1 (ar) C5 أجسام مضادة لـ وطرق لاستخدامها
CL2024000841A1 (es) Células inmunitarias que tienen arnhc coexpresados y sistemas de compuerta lógica
AU2019343184A8 (en) Compositions and methods for treating cancer with anti-CD123 immunotherapy
MX2021012003A (es) Anticuerpos multiespecificos contra antigeno de cancer de la bomba de eflujo y composiciones, reactivos, kits y metodos relacionados con los mismos.
MX2021010281A (es) Proteinas de enlace a antigenos que se enlazan al bcma.
WO2018048941A3 (en) USE OF BINDERS OF HIGH AFFINITY MONOCLONAL ANTIBODY PRODUCTS TO INCREASE THE ACTION TIME OF THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS IN BIOLOGICAL TISSUE
MX2022009355A (es) Anticuerpo anti-mdr1 y uso del mismo.
MX2024006968A (es) Anticuerpos cdh17 y metodos de tratamiento del cancer.
MX2018013523A (es) Anticuerpos monoclonales de adn dirigidos a il-6 y cd126.
PE20220596A1 (es) Anticuerpos que se unen a celulas cancerosas y que dirigen radionucleidos a dichas celulas
ZA202308896B (en) Antibodies binding trop2 and uses thereof
WO2019025865A3 (en) METHODS AND COMPOSITIONS FOR LIGAND-DIRECTED ANTIBODY DESIGN
AU2022214822A9 (en) Vector constructs for delivery of nucleic acids encoding therapeutic anti-tnf antibodies and methods of using the same
WO2019075300A3 (en) Mayaro virus consensus antigens, dna antibody constructs for use against mayaro virus, and combinations thereof
EA201892124A1 (ru) Днк-конструкции антител и способы их применения
EA202090671A1 (ru) Ограниченные условно активируемые связывающие белки
EA202192102A1 (ru) Днк-кодируемые привлекающие t-клетки биспецифические активаторы, нацеленные на раковые антигены, и способы их применения в противораковых терапевтических средствах